Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume 131, Issue 5, Pages 871-874Publisher
WILEY
DOI: 10.1038/sj.bjp.0703657
Keywords
vas deferens; human; sildenafil; zaprinast
Categories
Ask authors/readers for more resources
Sildenafil (0.1-30 muM), a cyclic GMP phosphodiesterase 5 (PDE 5) inhibitor, induced inhibition of electrically evoked contractions of ring segments of human vas deferens from 34 vasectomies. Zaprinast (0.1-100 muM), another PDE 5 inhibitor, and the nitric oxide (NO) donor sodium nitroprusside (SNP) (0.1- 100 muM) had no effect on neurogenic contractions. The inhibition induced by sildenafil was not modified by the inhibitor of guanylate cyclase 1H-[1,2,4]oxadiazolo[4,3-a] quinoxaline-1-one (ODQ) (1-30 muM) but it was abolished by the K+ channel blockers tetraethylammonium (TEA, 1 mM), iberiotoxin (0.1 muM) and charybdotoxin (0.1 muM). Sildenafil, zaprinast and SNP did not affect the contractions induced by noradrenaline. SNP (10 muM) caused elevation of cyclic GMP levels that was potentiated by sildenafil (10 muM) and zaprinast (100 muM). ODQ (10 muM) inhibited the increase in cyclic GMP. Sildenafil inhibits adrenergic neurotransmission in human vas deferens. The inhibition is not related to accumulation of cyclic GMP but is probably due to activation of prejunctional large-conductance Ca2+-activated K+ channels.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available